Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Veeva's subscription-led life-sciences cloud remains the company's core revenue driver.
  • New AI features are seen as incremental cross-sell and retention upside.
  • Analysts say AI does not materially change Veeva's valuation today.
  • Recommendation: consider a calibrated long position around $307 with a mid-term horizon.
  • Expect gains tied to post-earnings re-rating and new enterprise rollouts.
  • Use a defined stop-loss and modest upside target to manage risk.

Latest Articles

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Aug 3, 2026
Maya Rios
Press Releases

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Akebia Therapeutics announced the initiation of a Phase 2 basket trial evaluating ebribafusp, a novel complement inhibitor designed to treat rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to demonstrate safety, efficacy, and pharmacokinetics through weekly subcutaneous dosing over 26 weeks, with…

AKBA
EagleNXT Names Head of Sales and Business Development for Counter-UAS
Aug 3, 2026
Sofia Navarro
Press Releases

EagleNXT Names Head of Sales and Business Development for Counter-UAS

AgEagle Aerial Systems, traded as EagleNXT (NYSE: UAVS), announced the hiring of Lindsay A. Ryan, a 21-year U.S. Army aviation veteran, as Head of Sales and Business Development for their Counter-Unmanned Aircraft Systems (C-UAS) division. Ryan's extensive military experience and leadership in aviation are expected to drive sales growth and expand …

UAVS
Shoals Technologies Group and TerraFlow Energy Forge Multi-Gigawatt Partnership to Advance the Future of Energy Storage
Aug 3, 2026
Priya Menon
Press Releases

Shoals Technologies Group and TerraFlow Energy Forge Multi-Gigawatt Partnership to Advance the Future of Energy Storage

Shoals Technologies Group announced a strategic memorandum of understanding with TerraFlow Energy to collaborate on developing and deploying up to 5 GW annually of grid-scale long-duration energy storage, combining TerraFlow's vanadium flow battery technology with Shoals' power distribution systems for utility-scale and data center applications. Th…

SHLS
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Aug 3, 2026
Ajmal Hussain
Press Releases

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Anavex Life Sciences Corp. disclosed plans to refresh its board with two new independent directors possessing deep life sciences and regulatory expertise. The company has established an Executive Committee to manage its business and emphasized focus on advancing its lead Alzheimer's candidate, oral blarcamesine (ANAVEX®2-73), across multiple CNS in…

AVXL
Freedom Metals Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing August 4, 2026
Aug 3, 2026
Ajmal Hussain
Press Releases

Freedom Metals Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing August 4, 2026

Freedom Metals Acquisition Corp., a blank check company focused on mergers in the mining and critical minerals industry, announced that its Class A Ordinary Shares and Warrants will begin separate trading on Nasdaq starting August 4, 2026. Previously trading as combined units, shareholders can now trade shares under ticker FDMM and warrants under F…

FDMMU
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Aug 3, 2026
Hana Yamamoto
Press Releases

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

Taysha Gene Therapies and Catalent have expanded their partnership to include commercial manufacturing support for Taysha's investigational gene therapy TSHA-102 targeting Rett syndrome. The agreement ensures long-term commercial manufacturing capacity at Catalent's FDA-licensed facility, supporting a potential U.S. launch pending FDA approval. Thi…

TSHA
U.S. Moves to Make Visa Bond Program Permanent for Applicants from 50 Countries
Aug 3, 2026
Caleb Monroe
World

U.S. Moves to Make Visa Bond Program Permanent for Applicants from 50 Countries

The U.S. State Department is formalizing a visa bond requirement for citizens of 50 countries applying for B1 and B2 visas, allowing consular officers to demand bonds of up to $20,000. The decision follows a 2025 pilot and is presented as a tool to curb visa overstays; critics say it will discourage legitimate travel and raise barriers to legal ent…

Microsoft Shares Rise as Cloud, AI Milestones Drive Post-Earnings Momentum
Aug 3, 2026
Jordan Park
Stock Markets

Microsoft Shares Rise as Cloud, AI Milestones Drive Post-Earnings Momentum

Microsoft shares climbed in pre-open trading after a fiscal 2026 fourth-quarter report that beat expectations. The company reported $90 billion in revenue, a 18% year-over-year gain, with Azure revenue up 43% and crossing $100 billion in annual revenue. A rapidly expanding commercial order backlog and upgraded analyst views have bolstered investor …

Latigo Biotherapeutics Files to Raise Up to $288 Million in IPO
Aug 3, 2026
Avery Klein
Stock Markets

Latigo Biotherapeutics Files to Raise Up to $288 Million in IPO

Latigo Biotherapeutics Inc. has filed to raise up to $288 million in an initial public offering, proposing 16 million shares priced between $16 and $18. The clinical-stage company, which develops non-opioid pain treatments and is backed by Blue Owl Capital Inc., reported recent operating losses, a mid-2027 target for Phase 3 results and held $54.8 …

S&P 500 Monthly Review: Record Close Amid Rotation and Elevated Volatility
Aug 3, 2026
Jordan Park
Stock Markets

S&P 500 Monthly Review: Record Close Amid Rotation and Elevated Volatility

The S&P 500 closed at a record 7,489.72 on Aug 3, 2026, delivering a rolling one-year return of 20.1%. The advance followed a volatile sequence that began in early 2025, featuring a sharp spring selloff, heavy month-to-month swings, a rebound led by mega-cap technology, and intermittent rotation into cyclical sectors. Persistent speculative caution…

Nexera Enters into Letter of Intent for Exclusive Distribution Rights to Darknet Intelligence Platform for Data Centers
Aug 3, 2026
Hana Yamamoto
Press Releases

Nexera Enters into Letter of Intent for Exclusive Distribution Rights to Darknet Intelligence Platform for Data Centers

Nexera Technologies Ltd announced a letter of intent with Nebo Holdings Limited to become the exclusive worldwide reseller and distributor of Nebo's Preempt OSINT darknet intelligence software, targeting operators of data centers with threat detection services. The agreement, pending a technical proof of concept and due diligence, aims to expand Ne…

NEXR
Boris Nadezhdin Says He Has Left Russia, Posts Video from Paris
Aug 3, 2026
Derek Hwang
World

Boris Nadezhdin Says He Has Left Russia, Posts Video from Paris

Boris Nadezhdin, a 63-year-old former liberal lawmaker and outspoken critic of Russia's war in Ukraine, said he has left Russia and is currently abroad. In a short video posted on Telegram from the Eiffel Tower in Paris, he said he was "alive and free" and would outline his next steps later. His exit follows his inclusion on Russia's "foreign agent…

Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Aug 3, 2026
Caleb Monroe
Press Releases

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Helus Pharma announces the appointment of Michael Halstead as CEO to lead the company through critical late-stage clinical development and commercialization phases. Halstead brings 25 years of experience from Intra-Cellular Therapies, including a successful track record in drug development, launch, and commercialization. The company is advancing HL…

HELP